Communiqués Cynapsus Therapeutics Inc

Actions

CTH

CA23257Y8595

Recherche biotechnologique et médicale

Temps Différé Toronto S.E. Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^CAD	-.--%		+0,21%	-

03/06	HyProMag Ltd est détenue à 100% par Maginito Ltd, elle-même détenue à 79,4%/20,6% par Mkango Resources et CoTec	MT
03/06	HyProMag USA LLC est détenue à parts égales par CoTec et HyProMag Limited	MT

Communiqués

06/05	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
31/08/16	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
29/08/16	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
15/08/16	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
12/08/16	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
10/08/16	Cynapsus Therapeutics : Reports Second Quarter 2016 Financial Results and Recent Developments	GL
18/07/16	Cynapsus Therapeutics : Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
18/07/16	Cynapsus Therapeutics : Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
18/07/16	Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
06/07/16	Cynapsus Therapeutics : Announces 2016 Analyst and Investor Day	GL
06/07/16	Cynapsus Therapeutics Announces 2016 Analyst and Investor Day	GL
30/06/16	Cynapsus Therapeutics : Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson's Disease	GL
30/06/16	Cynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson’s Disease	GL
21/06/16	Cynapsus Therapeutics Announces Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders	GL
30/05/16	Cynapsus Therapeutics : Announces Data Presentations at the European Academy of Neurology Annual Meeting	GL
30/05/16	Cynapsus Therapeutics Announces Data Presentations at the European Academy of Neurology Annual Meeting	GL
20/05/16	Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors	GL
11/05/16	Cynapsus Therapeutics Reports First Quarter 2016 Financial Results and Recent Developments	GL
11/05/16	Cynapsus Therapeutics Announces Results of AGM	GL
28/04/16	Cynapsus Therapeutics to Present at Several Upcoming Investor Conferences	GL
15/04/16	Cynapsus Therapeutics : Announces Data Presentations at the American Academy of Neurology Annual Meeting	GL
15/04/16	Cynapsus Therapeutics : Announces Data Presentations at the American Academy of Neurology Annual Meeting	MW
15/04/16	Cynapsus Therapeutics Announces Data Presentations at the American Academy of Neurology Annual Meeting	GL
04/04/16	Cynapsus Therapeutics : and MonoSol Rx Announce Global IP Licensing Agreement	GL
04/04/16	Cynapsus Therapeutics : and MonoSol Rx Announce Global IP Licensing Agreement	MW